Alteogen Completes Phase 1 Clinical Trial of ADC Breast Cancer Treatment

[Asia Economy Reporter Hyungsoo Park] Alteogen announced on the 17th that it has completed the Phase 1 clinical trial of ALT-P7, the first domestically developed bio-better antibody-drug conjugate (ADC) breast cancer treatment.

The ADC breast cancer treatment developed by Alteogen is an improved bio-better drug. Phase 1 clinical trials were conducted at Samsung Seoul Hospital and Gachon University Gil Medical Center targeting patients with advanced or recurrent HER2-positive breast cancer. The safety and tolerability of ALT-P7 were confirmed.

Alteogen utilized its proprietary core technology for antibody-drug conjugation, a bio-better improvement technology. This core technology has been patented in nine countries worldwide. Using this unique platform improvement technology, in addition to the ADC breast cancer treatment, Alteogen is developing an ADC gastric cancer treatment registered as an orphan drug with the U.S. Food and Drug Administration (FDA). The ADC breast cancer treatment market size is expected to reach approximately 7 trillion KRW by 2024.

Including Alteogen, 10 companies such as global pharmaceutical firms AbbVie, AbGenomics, Daiichi-Sankyo, and ADC Therapeutics are conducting clinical trials. Recently, Japan's Daiichi-Sankyo licensed DS8201 to global pharmaceutical company AstraZeneca for up to $6.9 billion (7.8 trillion KRW). It received FDA approval in December last year.

A company official explained, "Interest in ADC anticancer treatments has increased following the recent 8 trillion KRW technology transfer of Daiichi-Sankyo's ADC breast cancer treatment." He added, "ALT-P7 is the only ADC breast cancer treatment in Korea to have completed Phase 1 clinical trials, and its technology is superior compared to multinational companies. We plan to enter Phase 2 clinical trials in the second half of this year to evaluate efficacy."

Alteogen is negotiating licensing-out agreements with multinational pharmaceutical companies. It is also developing an ADC ovarian cancer treatment, for which there is currently no therapy.